Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 25, 2014, 10:13:30 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 631842
  • Total Topics: 47836
  • Online Today: 293
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: The End of HIV Drug Development as We Know It?  (Read 1201 times)

0 Members and 1 Guest are viewing this topic.

Offline MYSTERY

  • Member
  • Posts: 186
The End of HIV Drug Development as We Know It?
« on: February 25, 2010, 06:20:08 PM »
The End of HIV Drug Development as We Know It?
A Blog Entry From CROI 2010

By Gerald Pierone Jr., M.D.

Feb. 18, 2010; 1:45 p.m. Pacific Time

 
Gerald Pierone Jr., M.D.
While scanning the CROI 2010 abstracts during my six-hour plane ride to San Francisco, the thought occurred to me that we may be witnessing the winding down of the HIV drug development process.

Historically, CROI has been a high-profile event during which pharmaceutical companies would showcase their up-and-coming investigational antiretroviral agents. Not anymore.

At this conference, the number of clinical trials of novel antiretroviral agents could be counted on one hand: Gilead's "quad" tablet, elvucitabine, vicriviroc and the ViiV integrase inhibitor S/GSK1349572. There were a few interesting antiretroviral agents presented, but never has there been such a wide gap between the number of investigational pre-clinical antiretroviral agents and the compounds that are actually moving through clinical development.


AdvertisementThere appear to be several reasons for this phenomenon. First and foremost, the bar for antiretroviral drug development has been raised to a very high level. Current combination therapy is not perfect, but about 80% of patients reach an undetectable viral load with minimal or manageable side effects. Furthermore, co-formulation of frontline antiretroviral therapy is becoming the standard, so a promising first-line agent without an already-established potential antiretroviral partner is at a disadvantage.

On the other end of the treatment spectrum, for an investigational agent looking for a niche among treatment-experienced patients, there is not a clear path forward to regulatory approval. For example, as Myles Helfand discussed in his blog, data presented at this meeting detailed the failure of the CCR5 inhibitor vicriviroc to outperform placebo in a salvage trial. The failure was not because of a lack of potency or side effects, but rather was related to the fact that the majority of patients in the placebo arm had more than two active agents in their optimized background regimen.

The misfortune that befell vicriviroc may have a chilling effect on future salvage trials. An ethical study design which would allow a potential salvage drug to demonstrate efficacy has yet to be articulated.



Atheist don't believe in GOD, but GOD believes in them and loves them. Never let the failure of man conflict with your love of GOD.

Offline mecch

  • Member
  • Posts: 11,225
  • red pill? or blue pill?
Re: The End of HIV Drug Development as We Know It?
« Reply #1 on: February 25, 2010, 08:04:52 PM »
The plot thickens.
“From each, according to his ability; to each, according to his need” 1875 K Marx

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.